Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Stem Cells Dev. 2010 Nov 9;20(6):1021–1029. doi: 10.1089/scd.2010.0198

Figure 5. Selective inhibition of CXCR7 but not CXCR4 diminishes the neuroprotection conferred by shScram CdM.

Figure 5

A) Addition of CXCR4 pharmacological inhibitor AMD3100 to shScram CdM increased mNPC survival by 22.7± 6.7% compared with DMSO control after 48 hrs in hypoxia (P = 0.0157). B, C) Addition of CXCR7 pharmacological inhibitor CCX771 to shScram CdM decreased mNPC survival by 36.5± 12.8% (B: P = 0.021) and mNPC number by 21 ± 6.7% (C: P = 0.049). mNPC viability and number was not different for cultures exposed to SFM with CCX771 or DMSO control. *P = 0.05.